I was just looking at comparables and Opzelura sold $61 million in Q4 for short-term atopic dermatitis and vitiligo; so say $240 million a year for 2 indications.
It looks like topical roflumilast is indicated for plaque psoriasis, will definitely be indicated for atopic dermatitis based on trial results, and is almost certainly going to gain indications for seborrheic dermatitis and (as a foam) scalp psoriasis. It is extremely well tolerated relative to other options out there.
This is setting aside the topical JAK and the biologic in preclinical.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.